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Background: Cost-effectiveness of percutaneous coronary intervention (PCI) using drug-eluting stents (DES) was compared to the costs of coronary 
artery bypass surgery (CABG) in patients with multivessel coronary artery disease in the first 5 years follow-up (FUP).
Methods: 199 patients with multivessel DES-PCI (n=114, 3.3±1.2 Taxus stents/patients) or CABG (n=85, 2.7±0.9 grafts/patients) were included. 
The incidence of major adverse cardiac and cerebrovascular events (MACCE: acute myocardial infarction (AMI), all-cause death, target vessel 
revascularization (TVR) and stroke), resource use and costs were analyzed prospectively over a 5-year FUP. Overall costs consisted of the baseline 
costs of the index procedure (PCI or CABG), clinical and angiographic procedure-related treatments during the entire FUP. The primary endpoint was 
cost-effectiveness of multivessel DES-PCI over CABG.
Results: At 5-year FUP, trend towards higher incidence of MACCE was observed in PCI (37.7%) as compared to CABG group (25.8%, p=0.06). In 
contrast, the occurrence of irreversible clinical end-points (AMI/death/stroke) was similar (25.4% vs 21.2% in PCI vs CABG groups). In-hospital costs 
were significantly less for PCI (11512 €/patients) than those with CABG (16063 €/patient). At 5-years, overall costs were still significantly higher for 
CABG patients (22330 €) as compared with PCI patients (16930 €), with a mean difference of 5399 €/patient. Incremental cost-effeectiveness ratio 
(ICER) calculation resulted in 45615 € to prevent 1 MACCE if CABG performed, and 8.4 patients should be treated with CABG rather than DES-PCI to 
result in 1 MACCE-free life. To prevent 1 AMI/death/stroke, additional 126.683 € would be needed, and 23.5 patients should be treated to save 1 
AMI/death/stroke-free life. Patients with high Syntax score (>32) profited more from CABG (MACCE rate 72.0% vs 47.1%, p<0.05), with an additional 
cost of 5440€/patient.
Conclusions: Multivessel DES-PCI in a real world setting led to a moderately higher rate of TVR and composite MACCE as compared to CABG, with 
significantly less costs over 5 year. Incidence of AMI/death/stroke was similar in the groups with significant more costs if CABG performed.
